Physical and mental health trajectories: A longitudinal SF-36 analysis in Alpha-1 antitrypsin deficiency-associated COPD

IF 3.5 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Respiratory medicine Pub Date : 2024-10-14 DOI:10.1016/j.rmed.2024.107838

{"title":"Physical and mental health trajectories: A longitudinal SF-36 analysis in Alpha-1 antitrypsin deficiency-associated COPD","authors":"","doi":"10.1016/j.rmed.2024.107838","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The Short Form 36-Item Health Survey (SF-36) is a health-related quality of life (HRQoL) measure validated in people with chronic obstructive pulmonary disease (COPD). While physical health is often more impaired than mental health in people with COPD, research on alpha-1 antitrypsin deficiency (AATD)-associated COPD is limited. This longitudinal study examines changes in physical and mental health in individuals with AATD and associated factors.</div></div><div><h3>Methods</h3><div>Analyses included participants of AlphaNet, a disease management program for individuals with AATD-associated lung disease who are prescribed augmentation therapy. Norm-based SF-36 scores for mental and physical component summaries (MCS and PCS) and 8 scales were analyzed. Linear mixed models evaluated mean changes in SF-36 scores over time.</div></div><div><h3>Results</h3><div>The study included 2165 participants (mean age 56.9 ± 10.0 years, 47.0 % female). At enrollment, mean PCS score was 37.5 ± 9.6, and mean MCS score was 51.9 ± 10.5. Mean mMRC dyspnea score was 2.3 ± 1.3; 54.6 % had ≥2 exacerbations annually, and 46.5 % used oxygen regularly. Average follow-up was 6.6 ± 3.2 years. The HRQoL remained stable; MCS improved by 0.16 points/year (p < 0.0001), while the PCS score declined by 0.49 points/year (p < 0.0001). Subscales followed similar trends.</div></div><div><h3>Conclusions</h3><div>At baseline, mental HRQoL scores were higher than physical HRQoL scores, indicating better mental health than physical health in this cohort with AATD-associated lung disease. Stable HRQoL with a slight improvement in mental scores over time and a small decrease in physical scores may be a unique feature of this cohort. Further studies are needed to correlate these findings with disease-specific instruments and patient physiology.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0954611124003135","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The Short Form 36-Item Health Survey (SF-36) is a health-related quality of life (HRQoL) measure validated in people with chronic obstructive pulmonary disease (COPD). While physical health is often more impaired than mental health in people with COPD, research on alpha-1 antitrypsin deficiency (AATD)-associated COPD is limited. This longitudinal study examines changes in physical and mental health in individuals with AATD and associated factors.

Methods

Analyses included participants of AlphaNet, a disease management program for individuals with AATD-associated lung disease who are prescribed augmentation therapy. Norm-based SF-36 scores for mental and physical component summaries (MCS and PCS) and 8 scales were analyzed. Linear mixed models evaluated mean changes in SF-36 scores over time.

Results

The study included 2165 participants (mean age 56.9 ± 10.0 years, 47.0 % female). At enrollment, mean PCS score was 37.5 ± 9.6, and mean MCS score was 51.9 ± 10.5. Mean mMRC dyspnea score was 2.3 ± 1.3; 54.6 % had ≥2 exacerbations annually, and 46.5 % used oxygen regularly. Average follow-up was 6.6 ± 3.2 years. The HRQoL remained stable; MCS improved by 0.16 points/year (p < 0.0001), while the PCS score declined by 0.49 points/year (p < 0.0001). Subscales followed similar trends.

Conclusions

At baseline, mental HRQoL scores were higher than physical HRQoL scores, indicating better mental health than physical health in this cohort with AATD-associated lung disease. Stable HRQoL with a slight improvement in mental scores over time and a small decrease in physical scores may be a unique feature of this cohort. Further studies are needed to correlate these findings with disease-specific instruments and patient physiology.

查看原文本刊更多论文

身心健康轨迹：对 Alpha-1 抗胰蛋白酶缺乏症相关慢性阻塞性肺病患者的 SF-36 纵向分析。

背景：简表 36 项健康调查（SF-36）是一种健康相关生活质量（HRQoL）测量方法，已在慢性阻塞性肺病（COPD）患者中得到验证。虽然慢性阻塞性肺病患者的身体健康往往比心理健康受损更严重，但有关α-1抗胰蛋白酶缺乏症（AATD）相关慢性阻塞性肺病的研究却很有限。这项纵向研究探讨了 AATD 患者身心健康的变化及相关因素：分析对象包括阿尔法网（AlphaNet）的参与者，阿尔法网是一项针对AATD相关肺部疾病患者的疾病管理计划，为他们提供增强治疗。分析了基于正常值的 SF-36 精神和身体部分总结（MCS 和 PCS）得分以及 8 个量表。线性混合模型评估了 SF-36 评分随时间的平均变化：研究共纳入 2165 名参与者（平均年龄 56.9 ± 10.0 岁，女性占 47.0%）。注册时，平均 PCS 得分为 37.5 ± 9.6，平均 MCS 得分为 51.9 ± 10.5。平均 mMRC 呼吸困难评分为 2.3 ± 1.3；54.6% 的患者每年病情加重次数≥2 次，46.5% 的患者定期使用氧气。平均随访时间为 6.6 ± 3.2 年。HRQoL 保持稳定；MCS 每年提高 0.16 分（p 结论：MCS 每年提高 0.16 分：在基线时，心理 HRQoL 分数高于身体 HRQoL 分数，这表明在这个患有 AATD 相关肺病的队列中，心理健康优于身体健康。随着时间的推移，心理评分略有提高，而身体评分略有下降，这种稳定的 HRQoL 可能是该队列的一个独特特征。还需要进一步研究，将这些发现与特定疾病的工具和患者的生理状况联系起来。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Respiratory medicine 医学-呼吸系统

CiteScore

7.50

自引率

0.00%

发文量

199

审稿时长

38 days

期刊介绍： Respiratory Medicine is an internationally-renowned journal devoted to the rapid publication of clinically-relevant respiratory medicine research. It combines cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions. Topics include adult and paediatric medicine, epidemiology, immunology and cell biology, physiology, occupational disorders, and the role of allergens and pollutants. Respiratory Medicine is increasingly the journal of choice for publication of phased trial work, commenting on effectiveness, dosage and methods of action.